Eli Lilly and Company (LLY) Rallies 7.75% After Earnings, EPS Exceeds Estimates, Sales Above Forecast

2026-02-04 · Stocks · QuoteReporter

Post Earning Analysis

Eli Lilly and Company (LLY) Rallies 7.75% After Earnings, EPS Exceeds Estimates, Sales Above Forecast

Eli Lilly & Co., founded in 1876 by Eli Lilly, is a leading pharmaceutical company headquartered in Indianapolis, IN. It specializes in the discovery, development, manufacture, and sale of pharmaceutical products, focusing on diabetes, oncology, immunology, neuroscience, and other therapeutic areas. Eli Lilly is committed to addressing complex medical challenges and improving health outcomes.

Eli Lilly has been spotlighted in recent news for its significant advancements and strategic positioning in the weight-loss drug market. The company announced that its weight-loss pill is on track for a Q2 launch in the U.S., with strong expectations surrounding its market impact. This news has led to a notable surge in Eli Lilly’s stock, which jumped following positive outlooks and earnings that exceeded forecasts. The performance of Eli Lilly’s weight-loss drugs, particularly Mounjaro and Zepbound, which reportedly saw sales doubling, has been a key driver of the company’s current financial success.

In contrast, Novo Nordisk has faced challenges, with warnings of a potential sales decline of up to 13% and a consequent 20% drop in its shares. This divergence in fortunes between Eli Lilly and Novo Nordisk highlights the competitive dynamics within the obesity drug market, where Eli Lilly seems to be gaining an upper hand.

These developments are critical for investors and stakeholders in Eli Lilly, suggesting a robust growth trajectory driven by its innovative treatments in the burgeoning market for weight-loss therapies. The positive earnings and forward-looking statements from Eli Lilly could provide a bullish case for the stock in the near term.

The current price of the asset at $1075.0 reflects a notable increase of 7.75% today, suggesting a bullish sentiment in the short term. This price is close to the week’s low of $993.58, up by 8.19%, and has rebounded significantly from this point, indicating strong buying interest near the lower price levels of the week.

Despite today’s gain, the asset is still down by 5.2% from the 52-week and YTD high of $1133.95, suggesting there might be a resistance level around this high. The price is considerably above the 52-week and YTD low of $621.5, showing a robust gain of approximately 72.97% from these levels, which highlights a strong upward trend over the longer term.

The moving averages show positive trends, with the price above the 20-day (1.7%), 50-day (1.91%), and significantly above the 200-day moving average (25.66%). This configuration supports a bullish outlook over multiple time frames.

The RSI at 54.93 indicates neither overbought nor oversold conditions, offering room for potential upward or downward movement. However, the negative MACD value (-3.38) suggests some caution, as it may indicate a recent loss in bullish momentum or a potential bearish crossover in the short term.

Overall, the asset exhibits a strong long-term upward trend with recent bullish behavior, but caution is warranted due to the negative MACD and the proximity to significant resistance levels.

Eli Lilly and Company (NYSE: LLY) reported a significant increase in its financial performance for the fourth quarter of 2025. The company’s revenue surged by 43% to $19.3 billion, up from $13.5 billion in the same quarter the previous year. This growth was propelled by strong sales across its key products, including a remarkable 110% increase in Mounjaro’s revenue to $7.4 billion and a 122% rise in Zepbound’s U.S. revenue to $4.2 billion.

Net income for the quarter also saw a substantial increase, growing by 50% to $6.6 billion. Earnings per share (EPS) followed suit, with reported EPS climbing by 51% to $7.39 and non-GAAP EPS rising by 42% to $7.54. The company’s gross margin improved slightly to 82.5%, reflecting a 0.3 percentage point increase.

Internationally, revenue grew by 43% to $6.4 billion, supported by favorable foreign exchange rates and increased sales volume. Research and Development expenses rose by 26% to $3.8 billion, emphasizing the company’s continued investment in innovation.

For 2026, Eli Lilly expects revenue to be between $80 billion and $83 billion, with non-GAAP EPS guidance ranging from $33.50 to $35.00. The company also increased its quarterly dividend by 15% to $1.50 per share, underscoring its strong financial health and commitment to shareholder returns.

Earnings Trend Table

The examination of EPS trends from Q4 2023 to Q1 2026 reveals a generally positive trajectory despite some fluctuations. Starting in Q4 2023, the company experienced a significant surprise with EPS turning positive against a negative estimate, showing a surprise percentage of 174.32%. Following this, there was a steady growth in reported EPS from Q1 2024 (2.49) to Q3 2024 (3.92), with the latter quarter showing a remarkable surprise of 50.92%. This upward trend faced a temporary setback in Q4 2024, where the reported EPS of 1.18 fell below the estimate by 19.54%, indicating a potential operational or market challenge.

However, recovery was evident by Q2 2025, as the reported EPS again exceeded estimates, culminating in Q1 2026 with an EPS of 7.54 against an estimate of 6.91, a 9.12% positive surprise. This pattern suggests resilience and an ability to exceed expectations, particularly notable in the substantial recovery and growth phases post-Q4 2024. The data points to effective strategic adjustments and perhaps an evolving business environment favorably impacting the company’s performance.

Dividend Payments Table

The review of the dividend data reveals a clear trend in the payment increments over the observed periods. Throughout 2024, dividends were consistently paid at a rate of 1.3 units per quarter. This pattern exhibits stability in the dividend disbursement during this year, suggesting a steady financial approach or a consistent earnings performance by the entity in question.

Transitioning into 2025, there is a noticeable increase in the dividend payments, rising to 1.5 units per quarter. This increase, maintained across all quarters of 2025, indicates a positive shift in the financial health or distribution strategy of the company. Such an upward adjustment could be reflective of increased profitability, a robust financial position, or a strategic decision to return more capital to shareholders.

Overall, the data points towards a financially stable entity with a capacity to increase dividend payouts, which could be a sign of confidence by the management in the ongoing and future profitability and stability of the company.

In the recent series of analyst ratings for Outer, there have been notable adjustments that reflect evolving market perceptions and financial forecasts for the company.

1. UBS – January 7, 2026: UBS resumed coverage on Outer with a “Buy” rating, setting a notably high target price of $1250. This resumption likely indicates UBS’s renewed confidence in Outer’s market position and growth prospects, positioning it as a strong investment opportunity.

2. Daiwa Securities – December 16, 2025: Daiwa Securities upgraded their rating from “Neutral” to “Buy,” with a new target price of $1230. This upgrade suggests a significant positive shift in Daiwa’s evaluation of Outer’s performance and potential, possibly due to new developments or improved financial results from the company.

3. Goldman – December 15, 2025: Goldman reiterated its “Buy” rating but adjusted the target price from $951 to $1145. This increase in target price reflects an optimistic revision based on perhaps better-than-expected quarterly results or market conditions favoring Outer’s business model.

4. BofA Securities – December 15, 2025: BofA Securities also reiterated a “Buy” rating but slightly lowered the target price from $1286 to $1268. Although this represents a minor decrease, it suggests a recalibration of expectations possibly due to market dynamics or slight shifts in company outlook, while still maintaining a strong buy position.

Overall, these rating changes indicate a generally positive outlook for Outer, with financial analysts showing confidence through high target prices and favorable ratings, albeit with slight adjustments reflecting ongoing market assessments.

The current price of the stock is $1075.00. Analyzing the recent analyst ratings, the consensus suggests a bullish outlook with an average target price significantly higher than the current market price. For instance, UBS has set a target price of $1250 following a recent resumption of coverage, indicating a potential upside. Similarly, Daiwa Securities upgraded their stance to ‘Buy’ from ‘Neutral,’ setting a target price of $1230. Goldman Sachs and BofA Securities also reiterated their ‘Buy’ ratings, updating their target prices to $1145 and $1268, respectively. These target prices suggest that analysts expect substantial growth, averaging around $1198.25, which represents an approximate 11.5% increase from the current price.

Unfortunately, specific details on earnings per share (EPS) trends and dividend policies were not provided, so a comprehensive analysis on these aspects cannot be completed at this time. However, the optimistic target prices imply expectations of strong financial performance in the future.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.